Name:
Tramadol (2-[(dimethylamino)methyl]-1-(3methoxyphenyl)cyclohexanol)
Type:
Opioid
AKA:
Tramadol
Tramadol (2-[(dimethylamino)methyl]-1-(3methoxyphenyl)cyclohexanol) image
Synthetic substance, no natural derivative
IUPAC Logo
Tramadol (2-[(dimethylamino)methyl]-1-(3methoxyphenyl)cyclohexanol) image
Tramadol, a synthetic opioid analgesic, was first introduced in the 1970s. It was developed to manage moderate to severe pain with a lower potential for abuse compared to other opioids. Tramadol's introduction marked a significant advancement in pain management. Its use has been associated with dependence and regulatory controls to address abuse potential.
Synthetic Substances Image
Tramadol is a synthetic opioid used for pain relief. It causes sedation and has mild stimulant effects, acting as a downer. Short-term use is effective for managing pain, but long-term use can lead to dependence, tolerance, and health issues. Overdose risks include respiratory depression and seizures. Safe use involves following prescribed dosages and monitoring for side effects. Recent research focuses on its efficacy and compares its risks with other opioids.
N/A
Tramadol, an opioid, affects serotonin and norepinephrine systems, causing euphoria and cognitive impairment. Immediate effects include mood enhancement and pain relief, lasting several hours. Long-term use can lead to dependence and psychological issues such as depression. Research indicates significant mental health risks with chronic use, including severe mood disturbances and potential for addiction.
N/A
Tramadol is a synthetic opioid used for pain management, with no significant historical or cultural lore. It gained prominence in the late 20th century as a pain medication. Modern cultural discussions focus on its benefits for pain relief versus its potential for dependence and abuse. Proponents emphasize its effectiveness and accessibility, while opponents warn of addiction risks. Its use is primarily medicinal, reflecting broader themes in pain management and the ongoing opioid crisis.
N/A